Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients

Last updated: May 4, 2020
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemorrhage

Gastrointestinal Diseases And Disorders

Chest Pain

Treatment

N/A

Clinical Study ID

NCT03785080
NOAC-GAP
  • Ages 18-99
  • All Genders

Study Summary

Current clinical society guidelines and statements are non-specific and relatively open-ended regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after gastrointestinal bleeding (GIB) in patients with atrial fibrillation (AF) who require the prophylactic medication for stroke prevention. These patients are at increased risk for devastating future thromboembolic events including stroke if NOAC is not resumed promptly, whilst premature resumption of anticoagulants can result in recurrent GIB, haemorrhage, anaemia, myocardial ischaemia and infarction in those with ischaemic heart disease, and even death. However, the question as to how early a NOAC can be safely restarted after acute GIB has not been previously answered, and there remains an important knowledge gap.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years

  • History of AF

  • Taking any kind of NOAC at the time of index acute GIB

  • Acute upper GIB (non-variceal bleeding lesions accounting for the GIB) with or withoutendoscopic treatment confirmed endoscopic haemostasis verified by GI specialist

  • Patient or next-of-kin able to provide informed consent

Exclusion

Exclusion Criteria:

  • Concomitant stroke (including TIA) at the time of index GIB

  • Requiring bridging IV heparin therapy

  • Portal hypertension

  • Known bleeding diathesis

  • Other conditions precluding use of NOAC at the time of randomisation

  • Pregnancy

  • Tumour bleeding

  • Antidote administration to reverse anticoagulation effect of NOACs

Study Design

Total Participants: 552
Study Start date:
March 11, 2019
Estimated Completion Date:
December 30, 2025

Study Description

The effectiveness and relative safety of NOACs have been demonstrated in large international studies where reductions in the incidence of stroke in patients with AF have been reported. However, the benefits of an anticoagulant are offset by increased incident rates of bleeding including gastrointestinal bleeding (GIB) and, less commonly, intracranial bleeding, warranting careful anticoagulation management during periods when patients are susceptible to the risks for bleeding, stroke and thromboembolism.

The exact duration for withholding NOAC after acute GIB is unknown and in general, current clinical society guidelines and statements are non-specific and relatively open-ended regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after gastrointestinal bleeding (GIB) in patients with atrial fibrillation (AF) who require the prophylactic medication for stroke prevention. These patients are at increased risk for devastating future thromboembolic events including stroke if NOAC is not resumed, whilst premature resumption of anticoagulants can result in recurrent GIB, haemorrhage, anaemia, myocardial ischaemia and infarction in those with ischaemic heart disease, and even death.

The purpose of this study is to determine if restarting NOAC very early after endoscopic haemostasis of bleeding peptic ulcer lesions is equivalent to early resumption in AF patients in terms of safety and efficacy for prevention of recurrent bleeding freedom from GIB recurrence, while maintaining undiminished benefits in reducing incident rates of systemic thromboembolism.

Connect with a study center

  • Blacktown Hospital

    Blacktown, New South Wales
    Australia

    Active - Recruiting

  • Endoscopy Center, Prince of Wales Hospital

    Hong Kong,
    Hong Kong

    Active - Recruiting

  • National University Hospital

    Singapore,
    Singapore

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.